Industry News: Integrated DNA Technologies expands access, expedites turnaround time, for minimal residual disease (MRD) solutions for cancer research

IDT’s xGen™ NGS solutions now fully support tumor-informed MRD research workflows from library preparation to hybridization capture

03 Feb 2023

To help researchers accurately measure circulating tumor DNA (ctDNA) from the most degraded and low-input samples, Integrated DNA Technologies has launched a complete MRD workflow for tumor-informed approaches. 

The launch expands access to IDT’s xGen MRD Hybridization Panel and xGen cfDNA & FFPE DNA Library Preparation Kit, which are now available as a bundled solution and aim to help scientists accelerate critical MRD research discoveries. IDT also developed the xGen MRD Hyb Panel Design Service and Ordering Tool, a new capability that empowers customers with self-guided ordering of up to 50 unique panels, each comprised of 2,000 probes, at the same time. Products are estimated to be shipped within five days from design approval. 

“To date, the primary challenge with MRD investigation has been the lack of sensitivity within existing tools to detect the low levels of circulating cell-free DNA present after cancer treatment,” said Steve Wowk, vice president, business unit and general management at IDT. “To fully realize the clinical utility MRD monitoring may provide, researchers are demanding assays capable of detecting low MRD concentrations, with the quality, speed, and reliability they can trust. We’re proud to make our MRD solutions more widely available to the research community, which depends on IDT to deliver the critical tools they need to continue advancing cancer breakthroughs.” 

Accurately measure MRD to improve cancer outcomes 

IDT’s xGen cfDNA & FFPE DNA Library Preparation Kit enables the identification of low-quality samples to discover rare variants such as cfDNA at less than 1 percent variant allele frequency (VAF). The xGen MRD Hybridization Panel, which delivers a custom solution for under $40 USD per sample, features a flexible panel size that targets mutations using up to 2,000 probes per panel, with the ability to order up to 50 panels at once. IDT’s MRD solutions are automation-friendly for high-throughput applications. 

Alternatively, IDT’s PCR analysis options—such as the oPools™ Oligo Pools—can accommodate multiplexed PCR workflows for MRD research. oPools Oligo Pools include up to 20,000 pooled oligonucleotides that can be from 40 to 350 bases in length. IDT scientific and design experts are available for additional customization to fit varied workflow needs. 

MRD to advance precision oncology by uncovering new cancer variants to accelerate research discoveries  

The MRD market is projected to surpass $3.7 billion USD by 2030, and MRD research continues to grow in popularity as the scientific community seeks to expand understanding of cancer disease progression and further improve patient outcomes. 

“Cancer remains a leading cause of death worldwide, and time is of the essence because more discoveries mean more life-saving advances,” added Wowk. “With its potential clinical utility on the horizon, IDT is well positioned to expand access to its MRD research offerings to offer quality solutions to genomics pioneers who are tirelessly working to bolster adoption of MRD and realize its full potential.” 

Want the latest science news straight to your inbox? Become a SelectScience member for free today >>